Remdesivir shows promise in preliminary coronavirus trial [Los Angeles Times (CA)]
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: Los Angeles Times
A preliminary report on COVID-19 patients treated with the experimental drug remdesivir suggests that the antiviral medication may lower the risk of death in severely ill patients and improve the condition of patients relying on a range of devices for breathing assistance. The safety and effectiveness of remdesivir as a treatment for coronavirus infection is being tested in clinical trials in the United States and around the world. Those studies will rigorously compare the drug against a variety of standard treatments to determine whether its benefits are real, and come without side effects that could put vulnerable patients in further danger. The report published Friday in the New England Journal of Medicine is among the first to detail the results of remdesivir use in patients whose conditions were meticulously recorded and tracked for 28 days. Among the study’s 53 patients, three-quarters got a full 10-day course of the drug and the remainder took it for between five and 10 days. S
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- Gilead (GILD) Valuation After Fresh Buy Rating and Extended Biktarvy Exclusivity Boost Investor Confidence [Yahoo! Finance]Yahoo! Finance
- Madonna pens scathing post against Trump for 'unthinkable' decision to ignore World AIDS Day [FOX News]FOX News
- Mableton man uses TikTok to fight HIV stigma as federal government skips World AIDS Day recognition [CBS News]CBS News
- Elton John reveals what would make Trump one of the 'greatest presidents' in history [FOX News]FOX News
- National AIDS Memorial Marks World AIDS Day with Two Signature Events Highlighting the Power of Communities to Shape Progress in the Fight Against HIV/AIDS and Advance Health and Social Justice [Yahoo! Finance]Yahoo! Finance
GILD
Earnings
- 10/30/25 - Beat
GILD
Sec Filings
- 12/1/25 - Form 4
- 12/1/25 - Form 4
- 12/1/25 - Form 4
- GILD's page on the SEC website